By New research presented this week at ACR Convergence 2022, the American College of Rheumatology’s annual meeting, showed that a higher dose of pneumococcal vaccine safely and effectively improved antibody response in patients receiving rituximab for ANCA-associated vasculitis.
Higher-dose pneumococcal vaccines improve immune response in ANCA-associated vasculitis patients receiving rituximab
Glass laboratory flasks on light table
Comments